HEALTHFINANCIAL TIMES WORLD
Moderna share price doubles on melanoma vaccine trial success
Moderna's share price doubled after announcing success in its melanoma vaccine trial. The company is developing this cancer vaccine in collaboration with Merck.
Related Signal
Adjacent reporting
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
- Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial
- Moderna CEO on Earnings, Flu Shots and Skin Cancer Trials
- STAT+: Moderna launches early trial of Ebola mRNA vaccine
- Moderna beat earnings expectations but its norovirus vaccine trial hit a wall